Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5‐fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost‐effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/).

[1]  U. Amstutz,et al.  Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity , 2014, International journal of cancer.

[2]  R. Greil,et al.  DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. , 2016, JAMA oncology.

[3]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[4]  P. Soulié,et al.  Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance , 2006, Molecular Cancer Therapeutics.

[5]  D. Sargent,et al.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). , 2014, Journal of the National Cancer Institute.

[6]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[7]  D. Kerr,et al.  Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Schellens,et al.  Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines , 2016, Cancer Chemotherapy and Pharmacology.

[9]  Kangsheng Wang,et al.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. , 2013, Cancer research.

[10]  Gabriel L. Butterfield,et al.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. , 2014, Cancer research.

[11]  U. Amstutz,et al.  Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy , 2015, Clinical Cancer Research.

[12]  Henk-Jan Guchelaar,et al.  Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. , 2016, Pharmacogenomics.

[13]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[14]  U. Hofmann,et al.  Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Vreken,et al.  Inborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspects , 1997, Journal of Inherited Metabolic Disease.

[16]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[17]  J. Schellens,et al.  Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? , 2016, Cancer treatment reviews.

[18]  H. McLeod,et al.  Characterization of the human dihydropyrimidine dehydrogenase gene. , 1998, Genomics.

[19]  R. Diasio,et al.  A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity , 2013, Clinical pharmacology and therapeutics.

[20]  C. Punt,et al.  Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer , 2011, Clinical Cancer Research.

[21]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[22]  Haiying Ding,et al.  Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis , 2016, Scientific Reports.

[23]  A. V. van Kuilenburg,et al.  Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. , 2016, British journal of clinical pharmacology.

[24]  D. Pezet,et al.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Schellens,et al.  Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Diasio,et al.  Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity , 2017, Clinical pharmacology and therapeutics.

[27]  J. Schellens,et al.  Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. , 2015, Pharmacogenomics.

[28]  R. Gilbertson,et al.  Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. , 2015, Neuro-oncology.

[29]  A. V. van Kuilenburg,et al.  Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. , 2014, Pharmacogenomics.

[30]  U. Amstutz,et al.  Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity , 2016, International journal of cancer.

[31]  F. Demard,et al.  Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. , 1992, Cancer research.

[32]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[33]  C. Borg,et al.  Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. , 2017, Seminars in oncology.

[34]  P. Vreken,et al.  Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. , 1997, European journal of cancer.

[35]  J. Ibrahim,et al.  A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. , 2014, The Oncologist.

[36]  J. Sanderson,et al.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[37]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[38]  Hans R Waterham,et al.  Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. , 2002, The Biochemical journal.

[39]  I. Fox.  Inborn errors of purine and pyrimidine metabolism. , 1976, Clinics of Perinatology.

[40]  E. Gamelin,et al.  5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. , 2007, Cancer letters.

[41]  U. Amstutz,et al.  Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. , 2009, Pharmacogenomics.

[42]  Gabriel L. Butterfield,et al.  microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites , 2014, Molecular Cancer Therapeutics.

[43]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.